PeptiDream Inc. (TYO:4587)
1,113.50
+5.00 (0.45%)
Aug 27, 2026, 10:54 AM JST
PeptiDream Employees
PeptiDream had 763 employees as of June 30, 2026. The number of employees increased by 6 or 0.79% compared to the same quarter last year.
Employees
763
Change
6
Growth
0.79%
Revenue / Employee
29.77M JPY
Profits / Employee
-5.62M JPY
Market Cap
142.52B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 763 | 6 | 0.79% |
| Mar 31, 2026 | 745 | 9 | 1.22% |
| Dec 31, 2025 | 645 | 24 | 3.86% |
| Sep 30, 2025 | 756 | 21 | 2.86% |
| Jun 30, 2025 | 757 | 12 | 1.61% |
| Mar 31, 2025 | 736 | 36 | 5.14% |
| Dec 31, 2024 | 621 | 18 | 2.99% |
| Sep 30, 2024 | 735 | 31 | 4.40% |
| Jun 30, 2024 | 745 | 53 | 7.66% |
| Mar 31, 2024 | 700 | 30 | 4.48% |
| Dec 31, 2023 | 603 | 34 | 5.98% |
| Sep 30, 2023 | 704 | 34 | 5.07% |
| Jun 30, 2023 | 692 | 53 | 8.29% |
| Mar 31, 2023 | 670 | 31 | 4.85% |
| Dec 31, 2022 | 569 | 392 | 221.47% |
| Sep 30, 2022 | 670 | 501 | 296.45% |
| Mar 31, 2022 | 639 | 481 | 304.43% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| GNI Group | 990 |
| Nxera Pharma | 322 |
| Japan Tissue Engineering | 200 |
| Healios K.K. | 75 |
| AnGes | 56 |
| Cuorips | 51 |
| Oncolys BioPharma | 45 |
| StemRIM | 45 |
PeptiDream News
- 13 days ago - Q2 2026 PeptiDream Inc. Earnings Presentation Transcript - GuruFocus
- 14 days ago - PeptiDream Earnings Call Transcript: Q2 2026 - Transcripts
- 14 days ago - PeptiDream Quarterly report: Q2 2026 - Filings
- 14 days ago - PeptiDream Slides: Q2 2026 - Filings
- 7 weeks ago - PeptiDream appoints three new executive vice presidents - TheFly
- 2 months ago - PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer - Business Wire
- 2 months ago - PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan - Business Wire
- 2 months ago - Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan - GlobeNewsWire